Helus Pharma (HELP) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Helus Pharma (HELP) has outperformed Kura Oncology (KURA) over the past year, gaining 75.0% versus a loss of 7.7%. Over five years, KURA leads with a -48.3% price change compared with -85.8% for HELP. Kura Oncology is the larger company by market cap ($807.8 million vs $770.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HELP | KURA |
|---|---|---|
| Share price | $10.55 | $9.08 |
| Market cap | $770.78M | $807.76M |
| 1-day change | -4.52% | -6.39% |
| YTD return | +28.97% | -12.61% |
| 1-year return | +74.96% | -7.72% |
| 5-year return | -85.84% | -48.29% |
| EPS (TTM) | $-4.15 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | — | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $15.15 | $13.90 |
| 52-week low | $3.76 | $7.36 |
| Distance from 52-week high | -30.36% | -34.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +279.34% | +250.77% |
| Average volume | 1.76M | 1.82M |
| Shares outstanding | 73.06M | 88.96M |
| Employees | 100 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed KURA by 82.7 percentage points over the past year.
About Helus Pharma
HELP stock →Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
HELP vs KURA FAQ
Which is bigger, Helus Pharma or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $770.78M for Helus Pharma (HELP).
Which stock has performed better over the past year, HELP or KURA?
HELP returned +74.96% over the past 12 months, compared with -7.72% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Helus Pharma and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.